UPDATE 1-Auxilium Q1 loss narrower than expected
* Q1 loss/shr $0.18 vs est loss/shr $0.32
* Q1 revenue $45.5 mln vs est $47.0 mln
May 3 (Reuters) - Auxilium Pharmaceuticals Inc (AUXL.O) posted a narrower-than-expected quarterly loss on strong U.S. sales of its testosterone gel Testim.
First-quarter net loss was $8.6 million, or 18 cents a share, compared with a loss of $13.2 million, or 31 cents a share, a year earlier. [ID:nWNAB5177]
Revenue rose 31 percent to $45.5 million.
U.S. product shipments of Testim rose 35 percent to $43.9 million.
Analysts on average had expected a loss of 32 cents a share, on revenue of $47.0 million, according to Thomson Reuters I/B/E/S.
Selling, general and administrative expenses rose 37 percent to $36.1 million for the quarter, mainly due to sales and marketing efforts for the launch of Xiaflex in the United States.
U.S. regulators had approved Xiaflex for treating a progressive hand disease known as Dupuytren's contracture in February, and the company launched the drug in early March. [ID:nN02119214]
Shares of the company closed at $35.60 Friday on Nasdaq. (Reporting by Esha Dey in Bangalore; Editing by Ratul Ray Chaudhuri)
- Alabama man gets $1,000 in police settlement, his lawyers get $459,000
- Probe: Athletes took fake classes at University of North Carolina
- Canadian police see no apparent links in Quebec, Ottawa attacks |
- Some U.S. hospitals weigh withholding care to Ebola patients
- Exclusive: Charred tanks in Ukraine point to Russian involvement